tetano
Editor, Senior Moderator
Hum Vaccin Immunother. 2018 Mar 21:0. doi: 10.1080/21645515.2018.1455476. [Epub ahead of print]
[h=1]Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.[/h] Nakashima K[SUP]1[/SUP], Aoshima M[SUP]1[/SUP], Ohfuji S[SUP]2[/SUP], Yamawaki S[SUP]1[/SUP], Nemoto M[SUP]1[/SUP], Hasegawa S[SUP]3[/SUP], Noma S[SUP]1[/SUP], Misawa M[SUP]1[/SUP], Hosokawa N[SUP]4[/SUP], Yaegashi M[SUP]5[/SUP], Otsuka Y[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] It is unclear whether simultaneous administration of a 23-valent pneumococcal polysaccharide vaccine (PPSV23) and a quadrivalent influenza vaccine (QIV) produces immunogenicity in older individuals. This study tested the hypothesis that the pneumococcal antibody response elicited by simultaneous administration of PPSV23 and QIV in older individuals is not inferior to that elicited by sequential administration of PPSV23 and QIV. We performed a single-center, randomized, open-label, non-inferiority trial comprising 162 adults aged ≥65 years randomly assigned to either the simultaneous (simultaneous injections of PPSV23 and QIV) or sequential (control; PPSV23 injected 2 weeks after QIV vaccination) groups. Pneumococcal immunoglobulin G (IgG) titers of serotypes 23F, 3, 4, 6B, 14, and 19A were assessed. The primary endpoint was the serotype 23F response rate (a ≥2-fold increase in IgG concentrations 4-6 weeks after PPSV23 vaccination). With the non-inferiority margin set at 20% fewer patients, the response rate of serotype 23F in the simultaneous group (77.8%) was not inferior to that of the sequential group (77.6%; difference, 0.1%; 90% confidence interval, -10.8% to 11.1%). None of the pneumococcal IgG serotype titers were significantly different between the groups 4-6 weeks after vaccination. Simultaneous administration did not show a significant decrease in seroprotection odds ratios for H1N1, H3N2, or B/Phuket influenza strains other than B/Texas. Additionally, simultaneous administration did not increase adverse reactions. Hence, simultaneous administration of PPSV23 and QIV shows an acceptable immunogenicity that is comparable to sequential administration without an increase in adverse reactions. (This study was registered with ClinicalTrials.gov [NCT02592486]).
[h=4]KEYWORDS:[/h] 23-valent pneumococcal polysaccharide vaccine; Elderly population; Immunogenicity; Quadrivalent influenza vaccine; Simultaneous administration
PMID: 29561248 DOI: 10.1080/21645515.2018.1455476
[h=1]Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.[/h] Nakashima K[SUP]1[/SUP], Aoshima M[SUP]1[/SUP], Ohfuji S[SUP]2[/SUP], Yamawaki S[SUP]1[/SUP], Nemoto M[SUP]1[/SUP], Hasegawa S[SUP]3[/SUP], Noma S[SUP]1[/SUP], Misawa M[SUP]1[/SUP], Hosokawa N[SUP]4[/SUP], Yaegashi M[SUP]5[/SUP], Otsuka Y[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] It is unclear whether simultaneous administration of a 23-valent pneumococcal polysaccharide vaccine (PPSV23) and a quadrivalent influenza vaccine (QIV) produces immunogenicity in older individuals. This study tested the hypothesis that the pneumococcal antibody response elicited by simultaneous administration of PPSV23 and QIV in older individuals is not inferior to that elicited by sequential administration of PPSV23 and QIV. We performed a single-center, randomized, open-label, non-inferiority trial comprising 162 adults aged ≥65 years randomly assigned to either the simultaneous (simultaneous injections of PPSV23 and QIV) or sequential (control; PPSV23 injected 2 weeks after QIV vaccination) groups. Pneumococcal immunoglobulin G (IgG) titers of serotypes 23F, 3, 4, 6B, 14, and 19A were assessed. The primary endpoint was the serotype 23F response rate (a ≥2-fold increase in IgG concentrations 4-6 weeks after PPSV23 vaccination). With the non-inferiority margin set at 20% fewer patients, the response rate of serotype 23F in the simultaneous group (77.8%) was not inferior to that of the sequential group (77.6%; difference, 0.1%; 90% confidence interval, -10.8% to 11.1%). None of the pneumococcal IgG serotype titers were significantly different between the groups 4-6 weeks after vaccination. Simultaneous administration did not show a significant decrease in seroprotection odds ratios for H1N1, H3N2, or B/Phuket influenza strains other than B/Texas. Additionally, simultaneous administration did not increase adverse reactions. Hence, simultaneous administration of PPSV23 and QIV shows an acceptable immunogenicity that is comparable to sequential administration without an increase in adverse reactions. (This study was registered with ClinicalTrials.gov [NCT02592486]).
[h=4]KEYWORDS:[/h] 23-valent pneumococcal polysaccharide vaccine; Elderly population; Immunogenicity; Quadrivalent influenza vaccine; Simultaneous administration
PMID: 29561248 DOI: 10.1080/21645515.2018.1455476